Introduction {#s1}
============

Coronary artery disease (CAD) has continued to be a major cause of morbidity and mortality worldwide, despite recent advances in medical and interventional therapies ([@B1]). The pathogenesis of acute coronary events involves the development of an early core with the accumulation of lipid-rich free cholesterol which then progresses to the formation of a fibroatheroma ([@B2]). Coronary angiography has been a crucial tool for detecting the gross presence of disease of coronary lesions, it however underestimates the magnitude of atherosclerosis in non-culprit arteries particularly in the early stages of disease process and provides no information regarding the composition of the plaque responsible for the lesion. Intracoronary imaging including intravascular ultrasound (IVUS) and near infrared spectroscopy (NIRS) have been studied to determine the plaque burden (PB) and plaque composition, respectively.

Intravascular Ultrasound provides 2-dimensional cross-sections of arterial vessels which enables the visualization and characterization of not just lumen and stent struts, but the vessel wall dimensions and the presence of plaques within it. In spite of the usefulness of IVUS in the study of plaques and vessel remodeling, it remains limited in the visualization and quantification of certain plaque characteristics mainly due to the inherent properties of sound waves ([@B3]). NIRS imaging offers the ability to penetrate blood and tissue to detect lipid core containing coronary plaques. The technology is based on the property of different organic molecules to scatter and absorb light at different intensities and wavelengths ([@B4], [@B5]). The integration of NIRS and IVUS systems has provided a hybrid imaging modality which combines the penetration and high resolution of IVUS with the lipid core quantification and characterization of NIRS which has been demonstrated to correlate with the lipid detection ([@B6], [@B7]).

We will review the present and potential clinical and research utility of NIRS-IVUS imaging in the study of coronary lipid plaques in the context of CAD.

Near Infrared Spectroscopy Technique {#s2}
====================================

Near-infrared diffuse reflectance spectroscopy is a technique that relies on the property of substances to absorb and scatter NIR light (wavelengths from 800 to 2,500 nm) at different intensities as a function of wavelengths ([@B8]--[@B10]). NIRS as a technique has been used in various science fields, including chemistry and pharmaceuticals, for the determination of the chemical composition of substances.

Prior to the development of NIRS, various spectroscopy techniques (nuclear magnetic resonance spectroscopy, Raman spectroscopy, and fluorescence spectroscopy) had been studied for possible intravascular applications toward the study of atherosclerotic plaques. The Raman near-infrared spectroscopy (NIRS) which was widely used several disciplines was based on the inelastic scattering of photons following collision with molecules and while it was suggested to have the potential to identify vulnerable plaques, was limited by signal-to-noise problems ([@B11]--[@B14]). The NIRS technology was first used in 1993 by Cassis and Lodder in animal experiments in which they sought the characterization of low-density lipoprotein cholesterol accumulation in the aortas of hypercholesterolaemic rabbits. This was followed by the *in-vivo* use of diffuse reflectance NIRS in imaging the lipid content in human carotid plaques exposed during surgery ([@B15], [@B16])

Validation of NIRS
------------------

In the early days of NIRS, 2 pivotal studies were carried out to validate its accuracy for the detection of lipid core plaques (LCPs) in human vessels. The first study by Gardner et al. made use of 84 human heart specimens- 33 hearts were used to develop NIRS algorithms and produce predefined endpoints while the remaining 51 hearts were used for prospective validation of algorithm, in a double-blinded study design, to evaluate the accuracy of NIRS in detecting LCPs. In order to have a quantitative target for constructing the algorithm and validating the findings, an LCP of interest was defined as a "fibroatheroma" (FA) with a lipid core \>60° in circumferential extent, \>200 μm thickness, and with a fibrous cap of mean thickness \<450 μm." The primary analysis which was done by comparing NIRS information presented on block chemogram readings vs. the classified histologic findings showed a "receiver operating characteristic (ROC) area under the curve (AUC) of 0.80 (95 % CI: 0.76--0.85)," confirming the ability of the NIRS system to accurately identify the LCPs ([@B4]).

Secondly, the Spectroscopic Assessment of Coronary Lipid (SPECTACL) study which was the first catheter-based technique to use NIRS in humans for percutaneous application was performed to validate the applicability of the autopsy-based LCP detection algorithm in patients. The study, in addition to showing that the NIRS imaging catheter had a similar safety profile to that of IVUS, demonstrated that the spectra obtained from imaging the epicardial vessels of living patients were similar to those from previously validated spectra from autopsy specimens, thereby supporting the use of NIRS for detection of LCPs in human patients ([@B9]).

Earlier, several *ex-vivo* studies had examined the ability of NIRS to identify histological features of lipid-rich atherosclerotic plaques in human blood vessels obtained at autopsy. These studies reported \>90% sensitivity and specificity for the identification of characteristic features suggesting lipid-rich plaques including the rupture-prone thin-cap fibroatheromas (TCFAs) seen in ACS patients. More recent studies have corroborated these findings as well as pointing to the additive value of NIRS to IVUS-derived PB in detecting vulnerable plaques ([@B17]--[@B21]).

Intra- and Inter-catheter reproducibility of the NIRS catheter has also been validated in a number of independent studies ([@B22], [@B23]).

Principles of Near Infrared Spectroscopy-Intravascular Ultrasound (NIRS-IVUS) Catheter
--------------------------------------------------------------------------------------

A little over a decade ago, a single modality NIRS system was originally developed for the invasive detection of lipid core plaques (LipiScan™, Infraredx Inc., Bedford, MA, USA). In later years, a dual modality system which combined IVUS with NIRS was developed to provide in a single catheter information on both vessel structure and plaque composition in a single acquisition. The NIRS-IVUS systems have continued to evolve and now exist in the form of a dual frequency, dual modality system. (TVC Imaging System™ and Makoto Intravascular Imaging System™, Infraredx Inc.) [Table 1](#T1){ref-type="table"}.

###### 

Evolution of NIRS/NIRS-IVUS imaging-based systems.

  ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  **Trade name**                **Model number**   **Year introduced (US)**   **Features/design specifications**                              **Advantages/improvements/revisions**                                                                                                                                                                                         **Additional comments**
  ----------------------------- ------------------ -------------------------- --------------------------------------------------------------- ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- --------------------------------------------------------------------------------------------
  LipiScan                      NIRS-MC5           2008                       NIRS (8,000 NIRS spectra/100 mm)                                First FDA cleared NIRS imaging System with two-dimensional map of LCP                                                                                                                                                         

  LipiScan IVUS                 TVC-MC7            2010                       NIRS (8,000 NIRS spectra/100 mm); 40 MHz, Grayscale IVUS        First FDA cleared dual imaging system which combined co-registered, grayscale, 40 MHz IVUS with proprietary NIR LCP detection technology to identify LCPs, degree of stenosis, reference vessel diameter, and plaque burden   

  TVC Imaging System            TVC-MC8            2012                       NIRS (32,000 NIRS spectra/100 mm); 40 MHz, Grayscale IVUS       First multimodality imaging to combine IVUS and NIRS. Improved IVUS Image quality and resolution with hydrophilic coating on catheter and added manual IVUS imaging features.                                                 1\. Lower frequency increases depth-of-field while the higher frequency improves clarity.\
                                                                                                                                                                                                                                                                                                                                                                            2. Improved resolution enhancing visualization of vessel details

  Advanced TVC Imaging System   TVC-MC8x           2014                       NIRS (32,000 NIRS spectra/100 mm); 35--65 MHz, Grayscale IVUS   High definition "HD" IVUS Image Quality with dual-modality frequency (up to 65 MHz) capabilities. Dual-layer hydrophilic coating. 40-micron axial resolution                                                                  

  TVC Imaging System            TVC-MC9            2015                       NIRS (32,000 NIRS spectra/100 mm); 35--65 MHz, Grayscale IVUS   Enhanced user interface and IVUS image with 20-micron axial resolution. Extended bandwidth rotational IVUS catheter.                                                                                                          

  Makoto Imaging System         TVC-MC10           2019                       NIRS (1,300 NIRS spectra/mm); 35--65 MHz IVUS                   User Interface Enhancements. Multiple (0.5, 1.0, 2.0 mm/s) Pullback Speeds. 0.0, 2.0, 10.0mm/s Manual IVUS tip movement speed                                                                                                 
  ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

*NIRS, Near-Infrared spectroscopy; FDA, Food Drug and Administration; TVC, True Vessel Catheterization; LCP, Lipid Core Plaque; IVUS, Intravascular Ultrasound; MHz, Megahertz (IVUS Transducer frequency)*.

The NIRS-IVUS system comprises a scanning NIR laser, a pullback and rotation unit, and a traditional IVUS-sized catheter. The 3.2F rapid exchange catheter has an entry profile of 2.4F and a shaft profile of 3.6F and is compatible with 6F guiding catheters. The NIRS-IVUS can be inserted over a 0.014-inch guide wire while its passage through the lesion is facilitated by the hydrophilic coating present on the flexible distal 50 cm end. The IVUS images are acquired during an automated pullback with simultaneous co-registered NIRS measurements. In the latest generation, the Makoto system, the catheter\'s imaging core pulls back at speeds of 0.5, 1.0, or 2.0 mm/s and rotates at 1800 rpm with a maximum imaging length of 15 cm, acquiring up to \~130,000 NIRS per 100 mm ([@B4], [@B9], [@B24]) ([Figure 1](#F1){ref-type="fig"}).

![NIRS Prototype figures **(A)** LipiScan-NIRS-MC5 **(B)** LipiScan-NIRS-MC5 Display **(C)** 2012 TVC Imaging System-MC8 **(D)** 2015 TVC Imaging System-MC9 **(E)** NIRS Pullback device **(F)** NIRS-IVUS catheter **(G)** 2012 TVC Display **(H)** Makoto Imaging System- MC10 **(I)** 2018 Makoto Display (All images in this Figure are licensed content by InfraRedX Inc. and shall not be reproduced).](fcvm-07-00107-g0001){#F1}

NIRS lipid core data are automatically displayed on a "chemogram" which displays the probability of the presence of a lipid rich plaque with the millimeters of pull-back on the x-axis and the circumferential position on the y-axis. Areas containing lipid core are displayed as yellow and those without any significant lipid core as red. A quantitative image metric is automatically reported as a numerical lipid-core burden index (LCBI), which represents the fraction of the chemogram yellow pixels whose probability of lipid exceeds 0.6, per 1,000. The LCBI provides a quantitative metric of the lipid core plaque present in a scanned vessel and can be computed over the entire length of a vessel scan, segments of scans, or defined width windows within segments (such as the 4 mm sliding window with the maximum LCBI, maxLCBI4mm) ([@B9]) ([Figure 2](#F2){ref-type="fig"}).

![**(A--C)** NIRS-IVUS chemograms in non-culprit lesions showing LCBI in non-stenotic angiographic segments; **(A)** Baseline Angiogram cine showing left anterior descending (LAD) segment with IVUS cross-sections and NIRS-IVUS rings indicating the presence of lipid plaque, **(B)** Baseline NIRS-IVUS chemogram (longitudinal view) showing the calculated maximum 4 mm LCBI (max4mmLCBI) in a 4 mm segment of the LAD segment shown in **(A)**. **(C)** Follow up angiogram of the same vessel segment showing a severely stenotic segment in the proximal LAD. (Courtesy of the MedStar Health Research Institute, MedStar Cardiovascular Research Network, Invasive Imaging Core Laboratory).](fcvm-07-00107-g0002){#F2}

Applications of NIRS-IVUS {#s3}
=========================

Lipid Rich Plaque Characterization
----------------------------------

Prior autopsy studies have shown that lesions with a thin fibrous cap(\<65 mn of cap thickness) overlying a large necrotic core are most frequently prone to rupture ([@B4], [@B25], [@B26]). These "vulnerable" plaques have therefore become a target for identification by novel intracoronary imaging modalities. Several studies in ACS patients have since shown the presence of LCPs in the culprit arterial segments to be major precursors of the disease and the possible association of the lipid core burden with adverse cardiovascular outcomes in CAD patients overtime ([@B27]--[@B34]) ([Table 2](#T2){ref-type="table"}).

###### 

Overview of key studies evaluating the utility and efficacy of NIRS-IVUS imaging in CAD.

  ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  **Study**                      **Year**   **Study aim**                                                                                                                                                                                          **Study design/**                    **Sample size reported**   **Follow-Up duration**   **NIRS related endpoint**                                                                                                                                                                                                                    **Key merits**                                                                                                      **Limitations**                                                       **Main conclusion**
  ------------------------------ ---------- ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------ ------------------------------------ -------------------------- ------------------------ -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- ------------------------------------------------------------------------------------------------------------------- --------------------------------------------------------------------- ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  The COLOR\                     2011       To determine whether intracoronary NIRS can identify plaques that are likely to cause periprocedural MI in patients undergoing elective PCI                                                            Prospective observational            62                                                  The rate of periprocedural MI in the groups with and without a large LCP in the treatment zone as assessed by NIRS and expressed as maxLCBI4 mm                                                                                              1\. Showed the relationship between the risk of periprocedural MI and NIRS-detected LCPs;\                          1\. Small sample size;\                                               NIRS imaging provides a rapid and automated means of LCP identification can be used to identify large, stenotic, coronary LCPs, which in the study were found to be associated with a 50% risk of periprocedural MI when dilated during PCI
  Trial ([@B35])                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         2. Included a comparison group of patients without large LCBI                                                       2. Selection bias due\                                                
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             to the availability of post-PCI biomarkers                            

  The YELLOW\                    2013       To evaluate the effect of short-term statin therapy on intracoronary plaque using FFR and NIRS-IVUS system in patients with multivessel CAD undergoing PCI and with at least 1 severely obstructive\   Randomized Clinical Trial            87                         7 weeks                  Change in lipid-core burden index at the LCBI4 mm max segment                                                                                                                                                                                1\. Evaluated the effect of therapeutics on NIRS- quantified lipid content;\                                        1\. Small sample size;\                                               Significant reduction in maxLCBI4mm in the intensive statin group vs the standard of care group
  Trial ([@B36])                            (FFR ≤ 0.8) non-culprit                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      2. NIRS imaging performed at baseline and follow-up;\                                                               2. Short follow-up duration;\                                         
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         3. Included correlation of physiology (FFR) against NIRS-derived LCBI;\                                             3. IVUS and NIRS were performed using separate catheters\             
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         4. Randomized study design                                                                                          4. Differences in baseline LCBIs between the two study groups         

  ATHEROREMO-NIRS\               2014       To determine the long-term prognostic value of\                                                                                                                                                        Prospective observational            203                        12 months                Composite of all-cause mortality, non-fatal ACS, stroke, and unplanned coronary revascularization exclusive of culprit lesion events                                                                                                         1\. Clinical endpoints;\                                                                                            1\. Small sample size;\                                               "CAD patients with an LCBI equal to or above the median of 43.0, as assessed by NIRS in a non-culprit coronary artery, had a 4-fold risk of adverse cardiovascular events at 1-year follow-up These findings relate to the risk throughout the entire coronary tree and not necessarily at the imaged segment or a lesion-specific risk"
  Oemrawsingh et al. ([@B37])               intracoronary NIRS as\                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       2. Results strongly suggested the prognostic value of NIRS imaging in non-stenotic, non-culprit segments            2. A single non-culprit coronary artery was imaged per patient        
                                            assessed in a non-culprit\                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             
                                            vessel in patients with CAD                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            

  The CANARY\                    2015       To determine whether pre-PCI plaque characterization using NIRS is capable of identifying lesions at risk of periprocedural myonecrosis                                                                Prospective Randomized Pilot Trial   85                                                  Incidence of periprocedural MI, defined as troponin or creatine kinase-myocardial band increase to 3 or more times the upper limit of normal within 72 h                                                                                     1\. Randomized design;\                                                                                             1\. Small study size;\                                                Pre-interventional intravascular imaging with a combined NIRS-IVUS catheter is able to identify lesions at increased risk of periprocedural myonecrosis after stent implantation Furthermore, the use of a
  Trial ([@B38])                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         2. Correlation of NIRS measures vs. MI enzyme parameters;\                                                          2. Not all clinically relevant MIs.                                   
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         3. Confirmed a relationship between NIRS-identified LRPs and periprocedural myonecrosis                                                                                                   

  IBIS-3 ([@B39], [@B40])        2016       To evaluate the effect of high intensity statin therapy on compositional coronary plaque changes using RF-IVUS and NIRS in non-culprit segments                                                        Prospective observational            103                        6 months-12 months       The effect of high intensity-rosuvastatin on LCP within non-stenotic NCLs                                                                                                                                                                    1\. Evaluated the effect of lipid lowering therapeutics on NIRS-quantified LCBI in non-stenotic segments;\          1\. Lack of a randomized design (no comparison group);\               High dose rosuvastatin therapy resulted in non-significant change in Necrotic Core (NC) and a neutral effect was observed in LCBI
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         2. Included study of the stability of the plaque necrotic core;\                                                    2. Events incidence not sufficient to assess MACE                     
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         3. NIRS imaging at baseline and follow-up                                                                                                                                                 

  The YELLOW II Trial ([@B41])   2017       Assess changes in plaque morphology using intravascular imaging, and evaluate cholesterol eflux capacity in stable multivessel CAD patients receiving high-dose statin therapy                         Prospective observational            85                         8--12 weeks              To examine lipid content changes in obstructive NCLs, measured by NIRS, and plaque morphology, assessed by OCT; and compare changes in lipid content and plaque morphology with changes in LDL, HDL, apo A-I, and macrophage functionality   1\. Study design included genetic, clinical and plaque parameters\                                                  1\. Lack of a randomized design/ comparison group\                    There was no significant change observed in plaque lipid content quantified using NIRS. But a significant increase in FCT of obstructive NCLs and enhancement of CEC in patients with stable coronary artery disease
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         2. Multimodality imaging- Included OCT imaging in assessing plaque                                                  2. Short follow-up duration                                           

  LRP Study\                     2019       To establish the relationship between LRPs detected by NIRS-IVUS at the non-culprit sites and subsequent coronary events from new culprit lesions                                                      Prospective cohort                   1,271                      24 months                Non-Index Culprit Lesion related Major Adverse Cardiac Events (NC-MACE) in patients and plaque in association with maxLCBI4 mm                                                                                                               1\. Large multicenter study design with clinical endpoints;\                                                        1\. Follow-up duration not extending beyond 2 years;\                 Coronary segments at higher risk of subsequent NC-MACE were associated with higher analyzable maxLCBI~4mm~ \> 400
  ([@B42], [@B43])                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       2. Included plaque and patient level endpoints;\                                                                    2. Only a few patients had all 3 major vessels scanned (average of\   
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         3. Largest intracoronary imaging study to identify patients and vessel segments at risk of future clinical events   2.1 vessels scanned/patient)                                          
  ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

**The PROSPECT** (Providing Regional Observations to Study Predictors of Events in the Coronary Tree) Trial, a landmark study which included 697 acute coronary syndrome (ACS) patients was a natural history study that sought to provide *in vivo* evidence of the hypothesis that the histopathological characteristic of plaques and not the degree of stenosis on angiography was responsible for the development of ACS. The study investigated the non-culprit coronary lesions in patients with ACS who underwent three-vessel gray scale and VH-IVUS imaging after successful PCI of culprit lesion demonstrated that "independent predictors of non-culprit-related events were the presence of VH-IVUS thin-cap fibroatheroma (hazard ratio 3.35; 95% confidence intervals 1.77--6.36), a PB ≥70% (hazard ratio 5.03; 95% confidence intervals 2.51--10.11), and a minimum lumen area ≤ 4.0 mm^2^ (hazard ratio 3.21; 95% confidence intervals 1.61--6.42)" ([@B44]).

Following the results from the PROSPECT Study, The **COLOR** registry prospectively observed a positive association between plaque morphology evaluated by NIRS and the degree of coronary artery stenosis. It demonstrated that increasing degree of stenosis seen by angiography was associated with more vulnerable plaque morphology as assessed by NIRS-IVUS system. Also, one of the first prospective human studies which evaluated high LCP by NIRS vs. cardiovascular events- The ATHEROREMO-NIRS (The European Collaborative Project on Inflammation and Vascular Wall Remodeling in Atherosclerosis---Near-Infrared Spectroscopy) trial, a sub-study of the ATHEROREMO-IVUS study of nearly 600 patients (to evaluate some of the limitations of VH IVUS identified after the PROSPECT and VIVA studies) produced promising results regarding the possibility of the technology. The relationship of LCBI value with the primary endpoint composite was found to be similar in both stable angina and ACS patients. In a more recent study, Matsumura et al. employed NIRS-IVUS in examining the features of coronary lesions with intraplaque hemorrhage (a key culprit in coronary lesion progression) in a histopathological validation study and demonstrated the presence of more FAs, greater IVUS PB and NIRS lipid core burden present in intraplaque hemorrhage segments compared to segments without intraplaque hemorrhage ([@B35], [@B37], [@B45]--[@B47]) [Table 2](#T2){ref-type="table"}.

In the most recent prospective multicenter natural history intracoronary imaging study---**The LRP (Lipid Rich Plaque)** identified patients and coronary segments at risk of future major adverse coronary events using NIRS-IVUS system. Patients with known or suspected CAD undergoing cardiac catherization with possible PCI were examined via NIRS-IVUS imaging in non-culprit arteries when possible. The study showed that 9% of the patients had subsequent non-culprit-major adverse cardiac events (NC-MACE) and out of these patients, higher event rate was associated with analyzable maxLCBI~4mm~ \> 400 (HR 3.39; 95% confidence interval 1.85--6.20), pointing to the diagnostic value of the NIRS-IVUS ([@B42], [@B43]). Following these results, the FDA granted a label claim for NIRS detection and identification of patients at increased risk of major adverse cardiac events (MACE) [Table 2](#T2){ref-type="table"}.

Clinical Applications of Intracoronary Near-Infrared Spectroscopy
-----------------------------------------------------------------

In general, the early evidence from NIRS-IVUS use points to multiple potential clinical applications of this imaging system. The identification and localization of vulnerable atherosclerotic plaques offers a clinical tool that could help assess precise lesion lengths including segments with a high lipid core burden toward optimal stenting ([@B48]). Secondly, NIRS-IVUS offers information on the necrotic core of atherosclerotic plaques and can predict the embolization of highly thrombogenic lipid depositions. The release of these elements into the blood stream which results in distal embolization is a known culprit in peri-procedural myonecrosis ([@B35], [@B38], [@B49]--[@B51]). Similarly, the utility of NIRS-IVUS in optimizing carotid artery stenting toward preventing periprocedural stroke is a subject of ongoing research ([@B52], [@B53]).

Furthermore, NIRS-IVUS has been employed in the study of plaque morphology and composition in the peripheral arteries-superficial femoral arteries in the setting of severe stenoses and symptomatic peripheral artery disease (PAD) ([@B54], [@B55]).

Several other studies ([@B37], [@B43], [@B56], [@B57]) which show the association of either max4mmLCBI or high LCBI (in the case of Danek et al. and Oemrawsingh et al.) in non-target/non-culprit vessel segment with increased incidence of MACCE and the risk of future coronary events subsequent to the presence of vulnerable plaques in non-culprit segments has given credence to retrospective autopsy studies regarding the assessment of plaque vulnerability. The ability of NIRS-IVUS to assess the possibility of future coronary events based on the LCBI values in non-culprit segments offers a unique diagnostic utility and a risk-stratification tool. The predictive role of NIRS-IVUS shown in these studies is being further studied in ongoing studies and raises the question of the need for treating non-culprit vulnerable plaques in vulnerable patients.

With the evolution of pharmacological therapies in addition to the performance of the present lipid-lowering therapies, NIRS-IVUS offers a tool for monitoring the effects of medications such as statins and PCSK9-inhibitors on the coronary vasculature lipid burden. Already, studies have investigated the effect of lipid-lowering medications on reducing necrotic-core containing plaques. The YELLOW (Reduction in Yellow Plaque by Aggressive Lipid-Lowering therapy) trial was a randomized clinical trial (rosuvastatin 40 mg daily vs. the standard-of-care lipid-lowering therapy) which recruited patients with multi-vessel CAD (including at least 1 severely obstructive \[FFR ≤ 0.8\] non-culprit) undergoing revascularization by PCI. The non-target lesions in both groups were evaluated at baseline and following 7 weeks of therapy with fractional flow reserve (FFR), and NIRS-IVUS, comparison between baseline and follow up results for NTLs demonstrated that reduction in LCBI4mm max was significantly higher in intensive statin group as compared to standard group ([@B36]) In a follow up study -the YELLOW II, the effects of high-dose statin therapy on changes in plaque morphology (evaluated by OCT) and plaque lipid content by NIRS were assessed in obstructive non-culprit lesions (NCLs) in addition to a comprehensive assessment of cholesterol efflux capacity (CEC) and peripheral blood mononuclear cell (PBMC) transcriptomics. The mean baseline NIRS-derived maxLCBI4mm was over 400 (416.6 ± 172.9) and the study reported no significant change in plaque lipid content by NIRS albeit a significant change in fibrous cap thickness after about 12 weeks of statin therapy. ([@B41]). Almost similarly, the IBIS-3 (Integrated Biomarker and Imaging Study 3) trial demonstrated that "high dose rosuvastatin therapy had a neutral effect on LCP (assessed by NIRS LCBI) in non-stenotic NCLs in the coronary vessels after 6- and 12-month follow-up intervals despite a relatively lower mean baseline maxLCBI4mm (201.9 ± 1623.8), in the cohort of 103 patients"([@B39], [@B40]). While differences in LCBI cut-offs of the various studies could be a possible reason for the discrepancy in findings, the mean baseline maxLCBI4mm in the YELLOW I and YELLOW II trials were similar, even though the baseline LCBI was significantly higher in patients randomly allocated to the intensive vs. standard therapy group in the YELLOW I and there was no comparative standard therapy group in the YELLOW II. There is also the question of short term LRP/LCBI regression occurring mostly in plaques with a large PB and large LRPs reported in a YELLOW trial sub-study evaluating the relationship between LRPs, plaque morphology and lesion progression or regression. These findings point to the need for further exploration of the effect of statins as well as novel lipid-lowering therapies on NIRS-derived LCPs and LCBI in conjunction with plaque morphology analysis via other intracoronary modalities ([@B58]).

Future Directions {#s4}
=================

The findings of Waksman et al. in the recent LRP study ([@B43]) strongly suggest the viability of NIRS-IVUS as a diagnostic and risk-stratifying modality and opens the door to further trials to evaluate therapeutic strategies against high lipid core burden and/or vulnerable plaques/patients in addition to studies which could explore the value of LCBI as a surrogate marker for the checking the effectiveness of new therapeutic interventions.

Notably, the effects of newer LDL-lowering medications are currently being studied in ongoing trials. The PACMAN AMI (Vascular Effects of Alirocumab in Acute MI-Patients) trial ([ClinicalTrials.gov](http://www.ClinicalTrials.gov) Identifier: NCT03067844) is examining the effects of PCSK9-inhibiting monoclonal antibody, alirocumab on coronary atherosclerosis in acute MI patients via NIRS, IVUS and OCT. Also, the FITTER (Functional Improvement of Coronary Artery Narrowing by Cholesterol Reduction With a PCSK9 Antibody) Trial ([ClinicalTrials.gov](http://www.ClinicalTrials.gov) Identifier: NCT04141579), will be enrolling patients to investigate the impact of evolocumab plus statins on FFR of non-infarct related arteries (non-IRAs) in multivessel disease patients and correlating baseline NIRS-derived lipid core burden with changes in FFR in the non-IRAs.

In a study design which integrates a natural history study and a randomized trial, the PROSPECT II and PROSPECT ABSORB, [ClinicalTrials.gov](http://www.ClinicalTrials.gov) Identifier: NCT02171065), patients with high risk plaque were randomized to receive Absorb BVS alongside the standard of care, optimal medical therapy (OMT) or vs. OMT alone and changes in the plaque will be evaluated by IVUS and NIRS at follow up. Lastly, The Preventive Coronary Intervention on Stenosis With Functionally Insignificant Vulnerable Plaque (PREVENT) study, is presently recruiting patients to determine the effect of preventive PCI on functionally insignificant coronary lesions with vulnerable plaque characteristics using NIRS, IVUS, OCT and virtual histology-IVUS modalities ([ClinicalTrials.gov](http://www.ClinicalTrials.gov) Identifier: NCT02316886).

While the value of NIRS-IVUS and other intracoronary imaging techniques are being shown in various imaging trials, there are still limitations in assessing plaque characteristics which could explain some of the conflicting study results. Multimodality imaging may be critical in overcoming these limitations, thus emphasizing the need for co-registration of NIRS-IVUS with other imaging including angiography and as well as OCT or in the form of hybrid imaging catheters ([@B59]). Finally, the ability of NIRS-IVUS to predict the location of histologically-confirmed TCFA and the possibility of NIRS-guided cap thickness detection, and collagen content analysis which are already being explored in *ex-vivo* studies could represent a huge breakthrough in vulnerable plaque studies in the near future.

Limitations {#s5}
===========

One of the main limitations of NIRS-IVUS is the invasiveness of the technique which precludes its use in primary prevention in symptomatic patients with subclinical disease. Presently, NIRS imaging does not have the capability to detect the depth of the lipid core or vulnerable plaque features such as the thinness of the fibrous cap.

Conclusion {#s6}
==========

NIRS in conjunction with IVUS is certainly a diagnostically useful tool for the detection of vulnerable plaques and can help identify patients at risk of future coronary events. While there is a wide spectrum of clinical applications for this technology, its viability for demonstrating the effects of present and forthcoming lipid-lowering therapies could significantly influence clinical perspectives and practice in the years to come.
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:   Intravascular ultrasound
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:   Near infrared spectroscopy

PB: Plaque Burden CAD

:   Coronary Artery Disease
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:   Percutaneous Coronary Intervention

LCP

:   lipid core plaques
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:   Lipid rich plaque
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:   Fibroatheroma
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:   Lipid core burden index

NC-MACE

:   Non culprit major cardiovascular events

MACE

:   Major adverse cardiac events

FDA

:   Food and Drug Administration

TCFA

:   thin-capped fibroatheromas
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:   Peripheral arterial disease

MACCE

:   Major Adverse cardiovascular and cerebrovascular events

FFR

:   Fractional Flow Reserve

RF-IVUS

:   Radiofrequency IVUS

BVS

:   Bioresorbable vascular scaffold.
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